Murine gammaherpesvirus 68 lMHV-68) is a rodent virus related to human Epstein-Barr virus lEBV). MHV-68 infection and its treatment were studied in a novel lethal immunosuppression model in BALBlc mice. Intranasally infected mice that were immunosuppressed with cyclophosphamide developed persistently high virus titres in pulmonary tissue, and to a lesser extent, in splenic tissue. These animals died from infection within 12 days, whereas normal mice resolved the infection by day 10 and survived. Cyclophosphamide-treated infected mice had significant decreases in natural killer cell activity, T and B cell proliferative responses, and T and B cell numbers compared to immunocompetent uninfected and infected animals. In order to study the treatment of the lethal infection, 16 known inhibitors of EBV or other herpesviruses were first evaluated against MHV-68 by plaque reduction assay in African green monkey kidney lMA-104) cells. Of these compounds, fialuridine lFIAU) had the most potent effect, inhibiting 50% of viral plaques at 0.1. !AM. By comparison, cidofovir lHPMPC), HPMPA, acyclovir and ganciclovir were inhibitory at 1.2, 0.9, 6.7 and 10 !AM respectively. Cyclophosphamide-immunosuppressed infected mice were treated intraperitoneally with acyclovir, FIAU, HPMPC or placebo for 5 days starting 24 h after virus = challenge. Acyclovir treatment 170 mg kg-1 day-l) did not increase survival time significantly but decreased lung virus titres sixfold as measured on day 9 of the infection; FIAU treatments 15 mg kg-1 day-l) caused a 2.4 day delay in death and reduced lung virus titres greater than 15-fold. HPMPC treatments 15 mg kg-1 day-l) resulted in a 13 day delay in death, and reduced virus production in the lung over 3000-fold compared with the placebo group. HPMPC appears to be an excellent candidate for treating EBV virus infections in humans, particularly in immunocompromised patients in whom infections may be life-threatening.
Introduction
Epstein-Barr virus (EBV), a gammaherpesvirus, is the aetiological agent of infectious mononucleosis and a number of lymphoproliferative diseases (Khanna et al., 1995) . Symptoms of mononucleosis in otherwise healthy individuals may range from mild fever to prolonged debilitating disease (Epstein & Achong, 1973) . EBV infections in immunosuppressed patients are usually more serious, for example X-linked immunodeficiency predisposes individuals to EBV disease where acute infection has a fatality rate as high as 75% (Purtilo et al., 1992) . AIDS patients may develop EBV-associated polyclonal lymphomas (Thomas et al., 1991) , Burkitt's lymphoma (Khanna et al., 1995) and oral hairy leukoplakia (Greenspan et al., 1985) . EBV-associated post-transplant lymphoproliferative disease can be a potentially fatal complication of chronic immunosuppression following. solid-organ or bone marrow transplantation (Papadopoulos et al., 1994) .
There is no specifically approved antiviral drug for treating EBV infections. Many nucleoside and nucleotide analogues have shown efficacy against EBV in cell culture (Lin et al., 1985 (Lin et al., , 1987 (Lin et al., , 1991 . The anti-herpesvirus drug acyclovir (ACV) reduced virus shedding in infectious mononucleosis patients but had no effect by itself on symptoms (Ernberg & Andersson, 1986) . Intravenous ACV combined with prednisolone used in similarly infected patients was reported to cause a dramatic clinical effect on pharyngeal symptoms and on fever (Andersson & Ernberg, 1988) . Regression oforal hairy leukoplakia has also been observed after ACV therapy (Resnick et al., 1988) , but the persistence ofEBV-infected B cells in virus carriers was not affected by ACV treatment (Yao et al., 1989) , which may explain its lack of effect on lymphoproliferative disorders (Zutter et al., 1988; Pirsch et al., 1989) .
Until recently, a small animal model for studying the treatment of gammaherpesvirus infections has not been available. EBV will infect owl monkeys, the common marmoset, the cotton-top tamarin and simian immunodeficiency virus-infected cynomolgus monkeys Cleary et al., 1985; Feichtinger et al., 1992; Wedderburn et al., 1984) , but not rats or mice. Severe combined immunodeficient (SCID) mice, which lack mature B or T cells, have been reported to succumb to multiple foci of proliferating EBV-positive human B cells derived from adult EBV-seropositive donors (Mosier et al., 1988) . The mice die 8 to 16 weeks after implantation of these cells. This model has been considered of limited value, however,as a model for EBV infection unless human epithelial cell implants can be shown to be infected in the scmmouse (Rickinson & Kieff, 1996) .
A new herpesvirus, originally isolated from small murine rodents in Czechoslovakia (Blaskovic et al., 1980) , was found to be related genetically to human EBV (Efstathiou et al., 1990) .This rodent virus, murine gammaherpesvirus 68 (MHV-68), is similar to EBV in that it latently infects B cells (Sunil-Chandra et al., 1992a , 1993 , and also causes self-limiting lung infections in susceptible mice (Sunil-Chandra et al., 1992b) . The splenomegaly occurring in MHV-68-infected mice is a characteristic of EBVinfections in humans (Usherwood et al., 1996) . Sunil-Chandra et al. (1994) studied the effects of ACV on MHV-68 infection in BALB/c mice. When used daily at 70 mg kg-l day-l, the drug suppressed viral titres at the peak of virus production (day 7) by approximately 1000-fold compared to placebo using a rigorous four times daily treatment regimen for 8 days starting 6 h after virus infection. In this model none of the animals died as a result of the self-limiting infection that developed.
We have further developed the MHV-68 animal model by immunosuppressing BALB/c mice with cyclophosphamide during the course of the infection. Under this profound immunosuppression, high virus titres develop in the lungs and the animals die from the infection. The enhancement ofdisease is comparable to that which occurs when murine cytomegalovirus (MCMV)-infected mice are similarly immunosuppressed (Smee et al., 1991) : This new MHV-68 animal infection model was characterized and then used to evaluate selected antiviral compounds found to be active in vitro against the virus.
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Materials and Experimental Procedures
Compounds
Acyclovir (ACV), ganciclovir (GCV), cyclobutylguanine (CBG), foscarnet (PFA), (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA), (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)cytosit:le (HPMPC), (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine (HPMPG), 9-(2-phos phonylmethoxyethyl)adenine (PMEA), 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP), acyclovir phosphonate (SR3722), ganciclovir phosphonate (SR3773), and ganciclovir cyclic phosphonate (SR3775) were obtained from previously indicated sources (Smee et al., 1995; Smee & Reist, 1996) . Cyclic HPMPC (cHPMPC) was kindly provided by N Bischofberger, Gilead Sciences (Foster City, Cali£, USA). 1-(2'-Deoxy-2' -fluoroarabinofuranosyl)-5-iodocytosine (FIAC), 1-(2'-deoxy-2'-fluoroarabinofuranosyl)-5 methyluracil (FMAU), and 1-(2'-deoxy-2'-fluoroarabinofuranosyl)-5-iodouracil (FIAU) were from Bristol Myers Squibb (Wallingford, Conn., USA). The compounds were prepared in sterile cell culture medium for in vitro work, and in sterile physiological saline for animal studies.
Virus and cells
MHV-68 was obtained from M Stancekova of the Faculty of Natural Sciences, Commenius University (Bratislava, Slovakia).The virus receivedwas designated as a wild-type strain of MHV-68. Two lines of African green monkey kidney cells were used: Vero (ATCC) and MA-104 (Microbiological Associates, Walkersville, Md., USA). They were propagated in Eagle's minimum essential medium (MEM) containing 10% fetal bovine serum (FBS) and 0.2% sodium bicarbonate. The FBS concentration was reduced to 2% for viral studies since confluent cell monolayers were used. Pools ofMHV-68 were prepared in Vero cells, aliquoted, and stored at -70°C. The MA-104 cells were used for plaque reduction assays, producing larger and more discernible virus plaques than Vero cells. Preliminary tests showed that the two cell lines gave similar results when testing compounds for antiviral activity against MHV-68. Vero cells were used to titrate virus recovered from mouse lungs, since they consistently detected 30-fold more virus than did MA-104 cells in parallel virus titrations. However, virus pools prepared from either cell line were similar in titre and in their ability to infect mice.
Tissue virus titre determination
Tissue virus was titrated by diluting 5% homogenates of liver, lung, salivary gland and spleen tissue prepared in MEM in 10-fold increments and assaying in 96-well plates of Vero cells. Each tissue sample was titrated separately using four wells per dilution. After 7 days of incuba-tion, the presence of virus in the wells was determined by development of cytopathic effect, with virus titres expressed as 10glO cell culture infectious doses per gram of lung tissue (loglOCCID so g-l) calculated by the method of Reed & Muench (1938) .
In vitro antiviral test methodology
Determinations of in vitro antiviral activities were made using a standard plaque reduction assay (Smee et al., 1995) . Briefly, virus was adsorbed to cell monolayers in 6well plates for 1-1.5 h, then virus-containing liquid medium was replaced' with test compounds in agarcontaining medium. Five concentrations of drug (in twofold dilution increments) were tested for a 7 day incubation period. After fixing the wells with 10% buffered formalin, removing the agar overlay, staining with 0.2% crystal violet in 20% ethanol, and rinsing off excess stain, the plaques were counted under 17x magnification using a Plaque Viewer (Belleo Glass, Vineland, N.J., USA). Fifty percent effective concentrations (EC so values) were determined from dose-response curves plotted on semi-logarithmic paper, using linear regression to connect the points. Because these compounds are known to not be cytotoxic or cytostatic to cells at 10~to 100-fold above EC so concentrations (Lin et al., 1985 (Lin et al., , 1987 (Lin et al., , 1991 Smee et al., 1995) , no assays to assess toxicity in uninfected cells were done.
Characterization of the disease in immunosuppressed mice
Female or male specific pathogen-free BALB/c mice weighing approximately 20 g each were obtained from Simonsen Laboratories (Gilroy, Calif., USA). They were quarantined 24 h prior to use and fed standard mouse chow and tap water ad libitum. Mice were treated intraperitoneally (i.p.) with 100 mg kg-1 day? of cyclophosphamide (Sigma) every four days starting 1 day before virus exposure. A similar group of mice was treated in parallel with saline. Infection was induced by exposing each anaesthetized mouse to 50 III (10 4 p.f.u.) ofMHV-68 administered intranasally. Anaesthesia was achieved by i.p. injection of 100 mg kg-1 of ketamine. On days 2, 4, 6, 9, 12, 15 and 20, ftve mice were randomly selected from the cyclophosphamide-or saline-treated groups, sacrificed, and their livers, lungs, salivary glands and spleens removed, weighed, and assayed for virus titre. On day 4, an additional five mice were sacrificed and their spleens were assayed for natural killer cell activity, splenic cell subpopulations, T cell and B cell proliferation. Deaths were recorded daily for 21 days in 9 mice per group.
In vivo antiviral methodology
BALB/c mice were immunosuppressed with cyclophosphamide and infected with MHV-68 as described above Antiviral Chemistry & Chematherapy 8(6) Murinegammaherpesvirus 68 immunosuppression model using a virus infecting dose of 105 p.f.u. per mouse. Treatments with selected antiviral compounds found to be active in the in vitro antiviral studies were given twice daily (8 am and 4 pm) for 5 days starting 24 h after virus challenge. ACV was administered i.p, at 70 mg kg-1 day", and FIAU and HPMPC were each injected i.p, at 5 mg kg-1 day'", This dosage of ACV was previously reported to inhibit MHV-68 replication in immunocompetent mice (Sunil-Chandra et al., 1994) . The FIAU dose was the same as we used previously for the chemically related FMAU, which was very active against herpesviruses in mice (Smee et al., 1985) . The dosage of HPMPC has been shown to be highly protective against MCMV in vivo (Smee et al., 1992) . Selection of these three antiviral agents (representing different chemical classes) for testing in mice was based upon in vitro potency, previous efficacy in vivo against MHV-68 or other herpesviruses, and availability of sufficient quantities of compound for testing.
Twenty mice were used in each treatment group; 10 were used to monitor survival and the remainder were sacrificed for lung virus titre determinations. Five mice per group were sacrificed on day 9, which just preceded the death of the placebo controls. The remaining 5 mice per group were intended to be euthanized later during the course of the infection. Because the ACV-and FIAUtreated infected mice died at a time near to the death of the placebo group, these remaining animals could not be taken at the later sacrifice time. The remaining 5 mice of the HPMPC group, which did survive the infection, were euthanized 21 days after infection for lung virus titre determinations. Three immunocompromised toxicity control mice were used for each compound evaluated and treated in an identical manner as the infected animals. These animals were weighed prior to start of therapy and again 18 h after termination of treatments; deaths, if they occurred, were recorded daily.
Assays for immune parameters
Natural killer (NK) cell activity was determined in splenic cells by their ability to lyse YAC-l tumour cells in a conventional 4 h chromium release assay (Warren et al., 1985) . Ratios of splenic cells to tumour cells used were 50:1 and 100:1. Cytotoxicity was expressed as percentage as-say was accomplished using spleen cells in 96-well microplates which were exposed to phytohaemagglutinin (PHA) , incubated at 3rC for 24 h, then pulsed with [3H]thymidine; following an additional 24 h incubation, the uptake of radiolabel was determined (Morrey et al., 1990) . The B celllymphoproliferative assay was done in the same manner using lipopolysaccharide (LPS) instead of PHA (Smee et al., 1991) .
Statistical methods
Immune parameter differences between groups were analysed statistically using the two-tailed Student's ttest. Increases in the mean day to death and reductions in viral titres were assessed using the two-tailed Mann-Whitney U test.
Results
The MHV-68-induced disease in immunocompetent and immunosuppressed mice was characterized. Following intranasal virus challenge, lung virus titres in immunocompetent mice reached maximum levels by 6 days after virus inoculation; these then decreased rapidly to undetectable levels in the majority of the lungs thereafter (Fig. 1a) . In contrast, lung virus titres continued to rise after day 6 in cyc1ophosphamidetreated mice, resulting in death of the animals by day 12. Spleen virus titres remained low in immunocompetent mice, but rose to over 10 5 loglO p.f.u. g-l in immunosuppressed animals (Fig. 1b ). Liver and salivary gland virus titres remained low in both treated groups of animals, with less than 10 3.6 loglO p.f,u. g-l virus detected (data not shown). Murine gammaherpesvirus 68 immunosuppression model The infection in the immunocompetent mice was relatively mild, with no animals dying of the infection, but with a moderate, albeit significant, increase in lung weight ( Fig. 2a ) denoting development of some lung consolidation due to the infection. The spleen weights (Fig. 2b) also were significantly increased in these animals, and slight increases in liverweight were seen (Fig. 2c) . Splenomegaly during infection of immunocompetent mice has been previously reported (Usherwood et al., 1996) . Striking lung consolidation was seen.in cyclophosphamide-treated animals as depicted by an over 300% increase in lung weight (Fig. 2a) . Liver, salivary glands and spleen weight declined significantly in this group during the infection (Fig. 2b,c,d) .
The immunological responses of mice during the infection are shown in Table 1 . Striking immunosuppression was seen in the cyclophosphamide-treated infected animals on day 4, which was 24 h after the second drug treatment. Cyclophosphamide-treated animals exhibited decreased NK cell activity, T and B cell proliferative responses, and in the numbers of splenic T cells. In immunocompetent mice, the infected animals showed similar immune responses and had similar immune cell numbers as the uninfected animals. The depression of immune parameters in cyclophosphamide-treated infected animals and the relative normality of these parameters in immunocompetent mice persisted until the end of the infection (data not shown).
The in vitro antiviral experiments were run to ascertain which compounds would be considered most appropriate for in vivo analysis. The results of these in vitro experiments are presented in Table 2 , with the compounds listed in the order of activity. The 2'-fluoro-2'-deoxypyrimidines FIAU, FMAU and FIAC were most effective, inhibiting plaque formation at less than 1 I-lM. The HPMP series of compounds, and PMEDAP were also quite potent, with sc., values less than 2~M. PMEA, CBG, SR3773, SR3775, ACV and GCV exhibited less potency against this in vitro infection; PFA was very weakly inhibitory with an EC so of 180 I-lM.
The in vivo antiviral experiment run in immunocompromised mice utilized the three most appropriate anti-MHV-68 compounds as determined in vitro. These compounds were FIAU, HPMPC and ACV, which represented a range of in vitro efficacies. The results of these studies are summarized in Table 3 . As was seen in the disease characterization experiment, the placebo-treated mice died between 10 and 12 days after virus challenge; the animals sacrificed on day 9 had a mean lung titre of 10 8 . 3 CCID so g-l of tissue. Treatment with ACV did not significantly delay death, but a sixfold inhibition of lung virus titre (P<O.05) at day 9 was noted. FIAU treatment delayed death 2.4 days (P<O.Ol), and reduced lung virus titres by over . In contrast to these moderate effects, HPMPC treatments resulted in a marked (13 day) delay in the mean day to death (P<O.Ol), and the amount of virus recovered from the treated mice was over lOOO-fold less (P<O.Ol) than in the placebo controls. None of the ACV-or FIAU-treated, infected animals or the placebo-treated controls survived to the day 21 sacrifice, but the HPMPC-treated mice euthanized at this time, 16 days after termination of treatment, had a mean lung virus titre of 7.5 loglo' indicating a rebound of virus replication, presumably after clearance of the drug from the animals.
None of the treatments with the three compounds 578 resulted in toxicity control deaths, but the animals treated with FIAU failed to gain weight (Table 3 ), suggesting the drug was only marginally tolerated at the 5 mg kg-1 day? dose used.
Discussion
The effects of cyclophosphamide on the immune system of mice have been well characterized by Selgrade et al. (1982) , who documented reductions in NK cell activity and on splenic cell (T cell and B cell) responses to PHA and LPS. This profound immunosuppression leads to an enhancement of certain viral infections, as was previously reported for murine cytomegalovirus-infected mice treated with the drug (Selgrade et al., 1982; Smee et al., 1991) . In this report, MHV-68 infection in immunosuppressed mice was shown to lead to lethal disease. We have also reproduced this effect in SCID mice infected intranasally with' MHV-68 (unpublished results), a follow-up of our work with lethal murine cytomegalovirus infections in SCID mice (Smee et al., 1992) . A difference was noted in the effects of MHV-68 and murine cytomegalovirus on the immune systems of immunocompetent mice. MHV-68 infection did not suppress immunity relative to uninfected animals, whereas murine cytomegalovirusinfection caused suppression of T cell and B cell proliferative responses (Smee et al., 1991) .
The infection of mice with MHV-68, even under severe immunosuppression, is primarily confined to the lung, and to a lesser extent, to the spleen. The results in cDifference between initial weight and weight 18 h after termination of treatment. dLog lO CCID so mL-I, determined 9 days post-inoculation.
-r-o.or.
immunocompetent mice confirm the work of other investigators (Sunil-Chandra et al., 1992b) . Salivary gland and liver are minor sites of virus replication. Increases in lung weight are consistent with lung consolidation due to infection. Cyclophosphamide treatment leads to dramatic decreases in spleen weight (Smee et al., 1991) due to elimination of immune cells, whereas infection of immunocompetent mice with MHV-68 causes splenomegaly due to increases in immune cell numbers (Usherwood et al., 1996) . These observations of enhanced MHV-68-induced disease in cyclophosphamide-treated mice mimic to some degree the reports of similarly enhanced disease in immunosuppressed human patients. Renal allograft recipients on long-term-immunosuppressive therapy display increased viral shedding and higher rates of spontaneous transformation in blood lymphocytes (Preiksaitis et al., 1992) . Young male children with X-linked immunodeficiency often succumb to a fatal infectious mononucleosis-like illness attributed to EBV (Purtilo et al., 1975) . Patients immunosuppressed due to HIV infection also show a shift in the balance of EBV disease, resulting in oral hairy leukoplakia (Greenspan et al., 1985) , in EBVassociated polyclonal lymphomas (Thomas et al., 1991) and in development of Burkitt's lymphoma (Khanna et al., 1995) . It is apparent that the development of this infection in mice with a normal immune system is significantly controlled by one or more of the immune factors assayed in this study.
The in vitro potencies of the compounds evaluated against MHV-68 closely paralleled the results with most of these inhibitors when tested against murine cytomegalovirus (Smee et al., 1995) , with the exception of acyclovir phosphonate (SR3722), which was less active in the present experiment. Many of the compounds appeared to be more potent (by at least 10-fold) against EBV than against MHV-68 (Lin et al., 1985 (Lin et al., , 1987 (Lin et al., , 1991 . This effect may be assay-dependent, however, or may have been influ-Antiviral Chemistry & Chemotherapy 8(6) enced by the viral multiplicities of infection used. An example of assay dependence is that reported for ACV against EBV, with EC so values of 0.3~by Lin et al. (1985) and 9!J.M by Bacon & Boyd (1995) being reported from different laboratories. ACV was less active against both EBV and MHV-68 than FIAC, FMAU, FIAU and the HPMP compounds (Lin et al., 1985 (Lin et al., , 1991 , indicating that the relative order of antiviral potency among the compounds is similar for inhibition ofEBV and MHV-68. Previously, ACV was reported to inhibit MHV-68 at 0.8 !J.M in baby hamster kidney (BHK-21) cells (Sunil-Chandra et al., 1994) , which is a greater potency than found in the present study run in MA-104 cells. This difference may be due to the cell lines used for assay, or because cloned virus was used in earlier studies (Sunil-Chandra et al., 1994) that may differ in drug sensitivity from the wild-type virus used in these experiments.
The effect of ACV was poor in this study compared to the results from the earlier report that the drug inhibited MHV-68 by lOOO-fold in normal mice (Sunil-Chandra et al., 1994) . In those studies, treatments were more intensive, being four times daily for 8 days starting 6 h after virus challenge. Virus was assayed on day 7, while treatments were still in progress, whereas in the present study treatments ended on day 5 and virus was assayed on day 9. This latter protocol allowed for substantial virus rebound during the four days that ACV treatments were not given. In addition, immunosuppression greatly enhances the severity of the infection, making it more difficult to treat, further accounting for the differences in ACV effect between the two studies.
Based upon the remarkable potency of FIAU in vitro against MHV-68, this compound was anticipated to have been very effective against MHV-68 in vivo. But this proved not to be the case. Similar to the results with ACV, the FIAU data suggest that lung virus titres were less inhibited during the treatment period or that the drug effect did not endure after the end of treatment. Thus, virus rebound was very rapid and death occurred only a few days after placebo-treated mice died.
It was not surprising that HPMPC greatly extended survival of MHV-68-infected mice, since this compound was previously shown to prolong the time to death in immunosuppressed mice infected with murine cytomegalovirus (Smee et al., 1992) . A 5 day course of treatment suppressed virus titres for many days after cessation of therapy, resulting in a 13 day increase in mean day to death. The diphosphate of HPMPC (the active antiviral metabolite) is known to have a prolonged intracellular half-life (Ho et al., 1992) , which accounts for why the drug effect persists long after treatment termination. This pharmacological property is being taken advantage of in the . treatment of humans infected with cytomegalovirus who receiveHPMPC maintenance therapy once every 2 weeks to suppress the infection (Polis et al., 1995) .
These MHV-68 animal studies suggest that the potency of ACV against EBV may not be sufficient for clinical efficacy. FIAU suffers from being overtly toxic to humans due to mitochondrial poisoning (Colacino et al., 1994) , and is no longer being investigated as a potential antiviral drug. HPMPC has the greatest potential for treating EBV disease. The compound was recently approved for treating cytomegalovirus retinitis in immunocompromised patients. One drawback to HPMPC is that it must be given intravenously due to poor oral absorption characteristics. For this reason it will not be given generally to treat infectious mononucleosis in otherwise healthy adults. But there may be a role for HPMPC in the treatment of more severe life-threatening EBV infections, particularly those occurring in immunocompromised persons.
As was pointed out earlier in this report, many similarities exist between infection of humans with EBV and of mice with MHV-68. Nevertheless, the viruses are antigenically different and prefer different sites of replication in their respective host. Other differences such as may occur in viral replication strategy have not been investigated. It will require further experimentation with new antiviral agents in humans and in mice to determine the overallutility of the MHV-68 model as a predictor of drug efficacy against EBV. The initial results appear to be encouraging.
